Rheumatoid Arthritis

A new study reframes rheumatoid arthritis, broadly considered to be a connective tissue disorder, as having deeper neurological ties.

In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.

A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.

Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.

Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

The TNF-inhibitor biosimilar was shown to fare similarly to the marketed therapy in a 52-week efficacy trial.

The study also found that the overall rate of cardiovascular events was low in the study population, indicating that statins aren’t required for all RA patients.

An aging US population, plus minimal non-invasive alternative options, determine the rate and scope of work an orthopedic surgeon sees today.

The first liquid formulation of the common gout therapy is anticipated to improve instances of dosing adjustment for patients.

The JAK1 inhibitor will be considered as a marketed once-daily therapy for moderate to severe RA in the second half of this year.

ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.

Madelaine A. Feldman, MD, touches on new developments in rheumatology including JAK inhibitor research, genetics and epigenetics, and personalized medicine.

Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.

The smaller, incomplete study is looking into both the efficacy and safety of the longtime therapy for patients with RA.

Repository corticotropin injection’s nearly six-decade history as a therapy has been tumultuous, but has most recently resulted in its use as an auto-immune drug.

The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.

Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

The findings led the team to believe a focus on treatment strategy, rather than disease activity, is more indicative of aortic distensibility improvement.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

Obesity in patients with rheumatoid arthritis has been found to influence the effectiveness of JAKi inhibitor treatments.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

Investigators assessed the risk of developing malignancies or serious infections with JAK inhibitors for RA treatment.

Patients with active rheumatoid arthritis who are cs/bDMARD-naïve may see a greater reduction in pain and improvement in physical function on baricitinib monotherapy compared with monotherapy of tocilizumab or adalimumab.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.

The updated label includes safety and efficacy data about the use of rituximab as follow-up treatment for patients with granulomatosis with polyangiitis and microscopic polyangiitis.

A subcutaneous formulation of tocilizumab (Actemra) is now approved for the treatment of active systemic juvenile idiopathic arthritis in patients at least 2 years old.

At 12 weeks, patients with rheumatoid arthritis receiving filgotinib responded and achieved low disease activity at significantly higher rates compared to placebo.